Iovance Biotherapeutics, Inc. financial data

Symbol
IOVA on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
825 Industrial Road, 4 Th Floor, San Carlos, California
State of incorporation
Delaware
Fiscal year end
December 31
Former names
Lion Biotechnologies, Inc. (to 6/5/2017), Genesis Biopharma, Inc (to 9/23/2013), FREIGHT MANAGEMENT CORP (to 3/8/2010)
Latest financial report
10-Q - Q2 2024 - Aug 8, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 412 % -18.9%
Quick Ratio 17.2 %
Debt-to-equity 28.1 % -8.12%
Return On Equity -65 % +17%
Return On Assets -50.8 % +15.3%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 304M shares +22.5%
Common Stock, Shares, Outstanding 297M shares +32.3%
Entity Public Float 1.4B USD -12.5%
Common Stock, Value, Issued 12K USD +33.3%
Weighted Average Number of Shares Outstanding, Basic 285K shares +26.9%
Weighted Average Number of Shares Outstanding, Diluted 285K shares +26.9%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 31.1M USD +12970%
Cost of Revenue 31.4M USD +1430%
Research and Development Expense 317M USD -1.64%
General and Administrative Expense 128M USD +22.4%
Costs and Expenses 492M USD +20.6%
Operating Income (Loss) -459M USD -7.21%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -446M USD +7.89%
Income Tax Expense (Benefit) -5.87M USD -206%
Net Income (Loss) Attributable to Parent -440M USD -5.11%
Earnings Per Share, Basic -1.68 USD/shares +25.3%
Earnings Per Share, Diluted -1.68 USD/shares +25.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 229M USD -0.58%
Accounts Receivable, after Allowance for Credit Loss, Current 31.6M USD +95670%
Inventory, Net 27.9M USD +187%
Assets, Current 482M USD +75.4%
Property, Plant and Equipment, Net 111M USD -1.41%
Operating Lease, Right-of-Use Asset 69.1M USD +2.21%
Other Assets, Noncurrent 327K USD +11.2%
Assets 964M USD +27.3%
Accounts Payable, Current 20.4M USD -34.5%
Accrued Liabilities, Current 61.8M USD +32.5%
Liabilities, Current 93.6M USD +5.64%
Deferred Income Tax Liabilities, Net 31.9M USD +57.6%
Operating Lease, Liability, Noncurrent 69.2M USD +0.58%
Liabilities 196M USD +9.54%
Accumulated Other Comprehensive Income (Loss), Net of Tax 526K USD +61.8%
Retained Earnings (Accumulated Deficit) -2.22B USD -24.7%
Stockholders' Equity Attributable to Parent 769M USD +32.8%
Liabilities and Equity 964M USD +27.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -122M USD -22.5%
Net Cash Provided by (Used in) Financing Activities 194M USD -25%
Net Cash Provided by (Used in) Investing Activities -112M USD -173%
Common Stock, Shares Authorized 500M shares 0%
Common Stock, Shares, Issued 297M shares +32.3%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -40.7M USD -113%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 235M USD -20.7%
Deferred Tax Assets, Valuation Allowance 447M USD +27.5%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure
Deferred Tax Assets, Gross 464M USD +26.4%
Operating Lease, Liability 80.7M USD +1.22%
Depreciation 10.3M USD +129%
Payments to Acquire Property, Plant, and Equipment 4.17M USD -26.4%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -440M USD -5.82%
Lessee, Operating Lease, Liability, to be Paid 126M USD -2.52%
Property, Plant and Equipment, Gross 145M USD +7.4%
Operating Lease, Liability, Current 11.4M USD +5.25%
Lessee, Operating Lease, Liability, to be Paid, Year Two 7.99M USD -3.56%
Lessee, Operating Lease, Liability, to be Paid, Year One 16.9M USD +58.4%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Deferred Income Tax Expense (Benefit) -1.41M USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 44.9M USD -8.57%
Lessee, Operating Lease, Liability, to be Paid, Year Three 8.19M USD +2.47%
Deferred Tax Assets, Operating Loss Carryforwards 256M USD +13.2%
Unrecognized Tax Benefits 26.1M USD +20.6%
Lessee, Operating Lease, Liability, to be Paid, Year Four 8.39M USD +2.48%
Operating Lease, Payments 17.1M USD +9.81%
Additional Paid in Capital 2.99B USD +26.7%
Amortization of Intangible Assets 18.1M USD +189%
Depreciation, Depletion and Amortization 11.9M USD +8.25%
Deferred Tax Assets, Net of Valuation Allowance 17.6M USD +2.91%